Is CytoDyn (CYDY) Stock Back To Rise Again?

Since last Wednesday CYDY has been stagnant but prepping more strength to survive the red stock market due to inflation. After announcing partial clinical hold of the HIV program and full clinical hold of covid-19 program CYDY had become a dead penny stock almost a month ago. However, 15 days ago CytoDyn informed us of an interesting paper about leronlimab again. This is most likely to be an anti-HIV drug if such development keeps occurring further in the next papers. Leronlimab is still going through clinical trials and suddenly may show some positive results in the upcoming weeks.

Before the CYDY stock soars or declines, visionary investors have already bought its shares in spite of looking for alternative ones. Sparing $1000 or less could be enough to test CYDY meanwhile it is under $0.50 stock in the OTC market.

cydy